Characteristics and Treatment of Anxiety Disorders in Parkinson's Disease
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Background: Anxiety disorders are common in Parkinson's disease ( PD ) and are undertreated. The current study investigates demographic and PD‐ specific factors associated with Diagnostic and Statistical Manual ( DSM ‐ IV ) anxiety disorders and subsyndromal anxiety in PD . It also examines the use of pharmacological and nonpharmacological treatments for anxiety in PD . Methods: Ninety nondemented PD patients completed a semistructured interview. Logistic regression models were constructed examining associations between several demographic, disease‐specific, and treatment factors, as well as both current syndromal, DSM ‐ IV anxiety disorders, and subsyndromal anxiety. Results: Associations were found between current DSM ‐ IV anxiety disorder, as well as female gender, younger age, more severe stages of PD , and poor activities of daily living. Subsyndromal anxiety was related to a younger onset age of PD . Relationships were also found between both anxiety groups and more complications of PD therapy, as well as higher depression scores. There were no associations between anxiety and levodopa equivalent daily dosage, motor disability, and cognition. In our sample, 57% of patients with current DSM ‐ IV anxiety disorders or subsyndromal anxiety were not currently treated with pharmacotherapy. Of those who currently received such treatment, 83% still experienced current anxiety disorders. Results suggest that anxiety is poorly recognized and treated in PD . Conclusions: Clinical trials investigating the efficacy of pharmacotherapy, tailored psychotherapy, and combination therapy primarily focusing on anxiety are much needed, with the aim of establishing novel targeted treatment protocols for the management of subtypes of anxiety disorders in PD .
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
JENKINSON, C., FITZPATRICK, R., PETO, V., GREENHALL, R., & HYMAN, N. (1997) · Age and Ageing · doi:10.1093/ageing/26.5.353 · Cited by 1,321
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.1.102 · Cited by 647
Cognitive-Behavioral Therapy for Depression in Parkinson's Disease: A Randomized, Controlled Trial
Dobkin, R. D., Menza, M., Allen, L. A., Gara, M. A., Mark, M. H., Tiu, J., Bienfait, K. L., & Friedman, J. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.10111669 · Cited by 310
Prevalence of anxiety disorders and anxiety subtypes in patients with Parkinson's disease
Pontone, G. M., Williams, J. R., Anderson, K. E., Chase, G., Goldstein, S. A., Grill, S., Hirsch, E. S., Lehmann, S., Little, J. T., Margolis, R. L., et al. (2009) · Movement Disorders · doi:10.1002/mds.22611 · Cited by 305 · cited 1×
“Whereas some studies have demonstrated a positive correlation between anxiety and duration of PD, others have shown no association.(1,8,9,32,36,37) Consistent with previous studies,(1,8,9,32,36,37) we did not find an association between anxiety and LEDD.”
ResultAnxiety in Parkinson's disease: identification and management
Chen, J. J., & Marsh, L. (2014) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285613495723 · Cited by 161 · cited 3×
“When psychological issues are addressed, pharmacological treatment is typically directed toward comorbid depression and anxiety is examined secondarily.(2) Despite the limited supporting evidence, benzodiazepines or selective serotonin reuptake inhibitors (SSRIs) are generally favored as the pharmacological treatment…”
BackgroundTroeung, L., Egan, S. J., & Gasson, N. (2013) · PLoS ONE · doi:10.1371/journal.pone.0079510 · Cited by 132 · cited 1×
“All other PD studies with SSRIs and SNRIs have focused on anxiety secondary to depression and have reported favorable outcomes; however, there is no robust empirical evidence to provide recommendations on choice of pharmacotherapy for anxiety in PD.(2,46)”
BackgroundThe clinical spectrum of anxiety in Parkinson's disease
Dissanayaka, N. N. N. W., White, E., O'Sullivan, J. D., Marsh, R., Pachana, N. A., & Byrne, G. J. (2014) · Movement Disorders · doi:10.1002/mds.25937 · Cited by 124 · cited 5×
“Prevalence estimates of anxiety disorders in PD range from 13% to 43%, and this variability has been largely attributed to differences in instrumental measures and diagnostic criteria.(3)”
BackgroundSelf-citationGeneralized anxiety disorder and the Hamilton anxiety rating scale in Parkinson's disease
Kummer, A., Cardoso, F., & Teixeira, A. L. (2010) · Arquivos de Neuro-Psiquiatria · doi:10.1590/s0004-282x2010000400005 · Cited by 103 · cited 2×
“Whereas some studies have demonstrated a positive correlation between anxiety and duration of PD, others have shown no association.(1,8,9,32,36,37) Consistent with previous studies,(1,8,9,32,36,37) we did not find an association between anxiety and LEDD.”
ResultTroeung, L., Egan, S. J., & Gasson, N. (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-19 · Cited by 85 · cited 1×
“Though there are no studies directly focused on the efficacy of psychotherapy for anxiety in PD, a few recent studies examining cognitive behavioral therapy for depression have shown potential benefits for comorbid anxiety in PD.(47,48) Given that a vast number of anxiety symptoms relate to symptomatology of PD, such…”
Background
Cited by
Prevalence of anxiety in Parkinson's disease: A systematic review and meta‐analysis
Broen, M. P. G., Narayen, N. E., Kuijf, M. L., Dissanayaka, N. N. W., & Leentjens, A. F. G. (2016) · Movement Disorders · doi:10.1002/mds.26643 · Cited by 457
“This is because rating scales may not capture symptoms of anxiety disorder NOS, which may be a predominant construct of PD-specific anxiety symptoms.(1,35,36) Furthermore, authors have used different cut-off scores, and the focus of specific anxiety symptoms may differ between rating scales.”
BackgroundSelf-citationMindfulness for Motor and Nonmotor Dysfunctions in Parkinson’s Disease
Dissanayaka, N. N. W., Idu Jion, F., Pachana, N. A., O’Sullivan, J. D., Marsh, R., Byrne, G. J., & Harnett, P. (2016) · Parkinson's Disease · doi:10.1155/2016/7109052 · Cited by 79
Self-citationAnxiety rating scales in Parkinson's disease: a critical review updating recent literature
Dissanayaka, N. N. W., Torbey, E., & Pachana, N. A. (2015) · International Psychogeriatrics · doi:10.1017/s1041610215000885 · Cited by 74
Self-citationCognitive Behavioral Therapy for Anxiety in Parkinsonʼs Disease: A Randomized Controlled Trial
Moonen, A. J. H., Mulders, A. E. P., Defebvre, L., Duits, A., Flinois, B., Köhler, S., Kuijf, M. L., Leterme, A., Servant, D., de Vugt, M., et al. (2021) · Movement Disorders · doi:10.1002/mds.28533 · Cited by 71
“Inclusion criteria for the caregiver, either partner, family member, or informal caregiver, were: (1) daily contact with the study participant; and (2) no severe medical or psychiatric conditions, as determined by a clinical interview.”
BackgroundCognitive-Behavioral Therapy for Anxiety in Parkinson’s Disease
Reynolds, G. O., Saint-Hilaire, M., Thomas, C. A., Barlow, D. H., & Cronin-Golomb, A. (2020) · Behavior Modification · doi:10.1177/0145445519838828 · Cited by 59
Metadata
- Authors
- Dissanayaka, N. N. W., White, E., O'Sullivan, J. D., Marsh, R., Silburn, P. A., Copland, D. A., Mellick, G. D., & Byrne, G. J.
- Venue
- Movement Disorders Clinical Practice
- Publisher
- Wiley
- Published
- 2015-04-06
- Volume
- 2
- Issue
- 2
- Pages
- 155-162
- ISSN
- 2330-1619 (ISSN-L)
- OpenAlex
- W2041433051
- Cited by
- 39
- References
- 9
- FWCI
- 1.62
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.